Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that co-administration of ketoconazole significantly altered the pharmacokinetics of dutasteride in rats, suggesting an interaction potential between dutasteride and azole antifungal drugs.

This guide reviews the biology of sebaceous glands and their evaluation methods, emphasizing their roles beyond lipid production in skin health and disease, and reports no new research results.

In this meta-analysis, researchers found that oral dutasteride may stabilize or improve frontal fibrosing alopecia in patients, but results varied widely, and further controlled studies are needed to confirm its effectiveness as a treatment option.

This study found that dutasteride use is associated with increased reports of sexual dysfunction, based on data from the U.S. Food and Drug Administration Adverse Event Reporting System.

This study found that metabolic syndrome negatively affected the response to intradermal dutasteride injection in female pattern hair loss, with participants showing reduced terminal hair and increased vellus hair compared to those without the syndrome.

This study found that dutasteride more effectively reduced serum dihydrotestosterone levels than finasteride in patients with benign prostatic hyperplasia.

This study found that longer exposure to 5α-reductase inhibitors significantly increased the risk of persistent erectile dysfunction, especially in younger men exposed to finasteride.

This study found that mesotherapy with a dutasteride-containing preparation improved hair growth indicators in female pattern hair loss better than saline, with minimal side effects and greater effectiveness in patients with shorter disease duration.

This study found that both finasteride and dutasteride effectively increased hair thickness in women with androgenetic alopecia over three years, with dutasteride performing better in women under 50 at specific scalp sites.

This study found that children with cancer showed more deviation from typical facial morphology compared to healthy controls, although the differences were not enough to distinguish patients from controls based on facial asymmetry alone.

In this prospective phase II clinical trial, researchers are investigating whether adding dutasteride to combined androgen blockade can improve the response rate and clinical outcomes for patients with androgen receptor-positive recurrent or metastatic salivary duct carcinoma.

This study reported that while no effective treatment exists for frontal fibrosing alopecia, oral 5-alpha-reductase inhibitors showed the most promise, inducing a good clinical response in 45% of patients.

This review examines the pharmacological properties and potential clinical benefits of 5α‐reductase inhibition in prostate cancer but reports no new research findings.

This review discusses the diagnostic criteria and management strategies for Polycystic Ovary Syndrome (PCOS) and highlights the need for comprehensive clinical assessment, but does not report new clinical findings.

This review discusses recent developments in hair restoration, highlighting the continued prominence of follicular unit strip surgery and the growing literature on the relatively new technique of follicular unit extraction, without presenting new clinical results.

This pilot study found that a novel regimen including NuH Hair led to significant hair growth in male patients with androgenic alopecia, regardless of atopy status, with quicker results when additional treatment components were used.

This study found that dutasteride treatment in pregnant mares significantly increased progesterone concentrations but did not alter gestational length or neonatal outcomes.

This review reports that nirmatrelvir-ritonavir has significant drug-drug interactions with many common dermatological medications, whereas molnupiravir may be an alternative therapy due to the absence of such interactions observed so far.

This study found that from 2011 to 2015, a substantial portion of women in the Netherlands dispensed finasteride or dutasteride were not using adequate contraception, prompting calls for improved risk management.

This review discusses plant-derived phytochemicals, such as phytosterols, polyphenols, and fatty acids, as potential alternatives to 5-alpha-reductase inhibitors for prostate cancer treatment, highlighting their promising anti-cancer properties and potentially fewer side effects compared to conventional drugs.

This article discusses the approval status of 5α-reductase inhibitors for androgenetic alopecia, noting finasteride is FDA-approved for certain men while dutasteride is not approved in the US for this condition; it reports no new results.

This study explored the effectiveness of injectable treatments for androgenetic alopecia, finding that dutasteride and growth factor formulations achieved clinically significant results compared to controls like saline and topical minoxidil, within selected trials from 2000 to 2023.

This article describes the use, action, and considerations for 5-alpha-reductase inhibitors in treating benign prostatic hyperplasia and androgenic alopecia but provides no new clinical results, emphasizing existing knowledge and guidelines for healthcare providers.

This study found that blood samples from donors on teratogenic drugs sometimes exceeded recommended concentration limits, suggesting a need for improved deferral policies.

In this study, the authors identified the DHRS9 SNP rs72623193 as most significantly associated with response to dutasteride in treating male pattern hair loss, with additional variants potentially contributing.

Dutasteride reduces DHT more effectively than finasteride.

Combining topical dutasteride with microneedling is more effective for hair growth than microneedling alone.

This article discusses frontal fibrosing alopecia, noting potential connections to lichen planopilaris, but reports no new clinical findings.

This article discusses the newly approved drug dutasteride for managing benign prostatic hyperplasia, but reports no new research findings; the authors advise obtaining complete information before prescribing.